Letter: Thalidomide in erythema nodosum leprosum. 1973

C L Crawford

UI MeSH Term Description Entries
D007918 Leprosy A chronic granulomatous infection caused by MYCOBACTERIUM LEPRAE. The granulomatous lesions are manifested in the skin, the mucous membranes, and the peripheral nerves. Two polar or principal types are lepromatous and tuberculoid. Hansen's Disease,Hansen Disease
D004893 Erythema Nodosum An erythematous eruption commonly associated with drug reactions or infection and characterized by inflammatory nodules that are usually tender, multiple, and bilateral. These nodules are located predominantly on the shins with less common occurrence on the thighs and forearms. They undergo characteristic color changes ending in temporary bruise-like areas. This condition usually subsides in 3-6 weeks without scarring or atrophy.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013792 Thalidomide A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action. Sedoval,Thalomid

Related Publications

C L Crawford
October 1973, Lancet (London, England),
C L Crawford
May 1990, DICP : the annals of pharmacotherapy,
C L Crawford
June 1988, Leprosy review,
C L Crawford
January 1983, Acta leprologica,
C L Crawford
August 1973, Lancet (London, England),
C L Crawford
October 2009, Therapeutic drug monitoring,
C L Crawford
January 2010, Revista da Sociedade Brasileira de Medicina Tropical,
C L Crawford
October 2001, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
Copied contents to your clipboard!